Over deze podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
270 afleveringen · Levenswetenschappen
BioSpace
Nieuwste afleveringThe decisions behind scientific progress
Over deze podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Recente afleveringen
- J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback14 okt · 20 min
- Beyond equity: Why venture debt is reshaping European biotech8 okt · 23 min
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more7 okt · 24 min
- The race for access: How the FAIR Act could reclaim U.S. biotech leadership1 okt · 20 min
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll30 sep · 20 min
- How radioligand therapy is rewriting cancer care24 sep · 16 min
- Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz23 sep · 21 min
- When vision fades: Rethinking wet AMD and the durability gap17 sep · 22 min
- FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival16 sep · 22 min
- Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease9 sep · 20 min
sharemy.show/biospace
Voor op een poster of slide.